Company intelligence / Profile preview
Aculeus Therapeutics
Melbourne / Parkville, Victoria, Australiaaculeustx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aculeus Therapeutics develops small molecule drugs that modulate the immune system, primarily targeting the STING pathway for cancer treatment. Their lead programs were in‑licensed from the CRC for Cancer Therapeutics in Australia. The company operates with a semi‑virtual model, leveraging both internal expertise and external collaborations with CROs and consultants. The most advanced program appears to be preclinical or early clinical, with ongoing optimization and combination therapy studies.
- Therapeutic areas
- OncologyOther
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
In‑licensed assets from CRC for Cancer Therapeuticsworks with Australian/international CROs and former CRC participants
Beyond the preview
Go deeper on Aculeus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aculeus Therapeutics.